Cellini Miriam, Santaguida Maria Giulia, Gatto Ilenia, Virili Camilla, Del Duca Susanna Carlotta, Brusca Nunzia, Capriello Silvia, Gargano Lucilla, Centanni Marco
Department of Medico-Surgical Sciences and Biotechnologies (M.Cel., M.G.S., I.G., C.V., S.C.D.D., N.B., S.C., M.Cen.), "Sapienza" University of Roma, and Endocrinology Unit (M.Cel., S.C.D.D., N.B., L.G., M.Cen.), Azienda Unita Sanitaria Locale Latina, 00040, Latina, Italy.
J Clin Endocrinol Metab. 2014 Aug;99(8):E1454-8. doi: 10.1210/jc.2014-1217. Epub 2014 May 5.
An increased need for T4 has been described in patients with different gastrointestinal disorders. However, there is a lack of systematic studies assessing the need for T4 in hypothyroid patients with lactose intolerance, a widespread and often occult disorder.
The objective of the study was to assess the replacement T4 dose required in hypothyroid patients with lactose intolerance.
This was a cohort study.
The study was conducted at an outpatient endocrinology unit in a University Hospital.
The replacement T4 dose has been analyzed, from 2009 to 2012, in 34 hypothyroid patients due to Hashimoto's thyroiditis and lactose intolerance and being noncompliant with a lactose-free diet.
An individually tailored T4 dose was measured.
In all patients with isolated Hashimoto's thyroiditis, target TSH (median TSH 1.02 mU/L) was obtained at a median T4 dose of 1.31 μg/kg/d. In patients with lactose intolerance, only five of 34 patients reached the desired TSH (median TSH 0.83 mU/L) with a similar T4 dose (1.29 μg/kg/d). In the remaining 29 patients, the T4 dose was progressively increased and the target TSH (median TSH 1.21 mU/L) was attained at a median T4 dose of 1.81 μg/kg/d (+38%, P < .0001). In six of these patients, other gastrointestinal disorders were diagnosed, and their median T4 requirement was higher (2.04 μg/kg/d; +55%; P = .0032). In the remaining 23 patients with isolated lactose intolerance, a median T4 dose of 1.72 μg/kg/d (+31% P < .0001) has been required to attain pharmacological thyroid homeostasis.
These findings show that lactose intolerance significantly increased the need for oral T4 in hypothyroid patients.
不同胃肠道疾病患者对甲状腺素(T4)的需求增加。然而,对于乳糖不耐受(一种普遍且常隐匿的疾病)的甲状腺功能减退患者,缺乏评估其对T4需求的系统性研究。
本研究的目的是评估乳糖不耐受的甲状腺功能减退患者所需的T4替代剂量。
这是一项队列研究。
研究在一所大学医院的门诊内分泌科进行。
2009年至2012年期间,对34例因桥本甲状腺炎和乳糖不耐受且不遵守无乳糖饮食的甲状腺功能减退患者的T4替代剂量进行了分析。
测量个体化定制的T4剂量。
在所有单纯桥本甲状腺炎患者中,T4剂量中位数为1.31μg/kg/d时达到目标促甲状腺激素(TSH,中位数TSH 1.02mU/L)。在乳糖不耐受患者中,34例患者中只有5例使用相似的T4剂量(1.29μg/kg/d)达到了期望的TSH(中位数TSH 0.83mU/L)。在其余29例患者中,T4剂量逐渐增加,T4剂量中位数为1.81μg/kg/d(增加38%,P <.0001)时达到目标TSH(中位数TSH 1.21mU/L)。其中6例患者被诊断出患有其他胃肠道疾病,他们的T4需求中位数更高(2.04μg/kg/d;增加55%;P =.0032)。在其余23例单纯乳糖不耐受患者中,达到药理学甲状腺稳态需要T4剂量中位数为1.72μg/kg/d(增加31%,P <.0001)。
这些发现表明,乳糖不耐受显著增加了甲状腺功能减退患者对口服T4的需求。